Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Frexalimab by Sanofi for Systemic Lupus Erythematosus: Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Frexalimab by Sanofi for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData,...
Frexalimab by Sanofi for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According to...
Risk adjusted net present value: What is the current valuation of Sanofi's Frexalimab?
Frexalimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS). According...
Frexalimab by Sanofi for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to...
Frexalimab by Sanofi for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to...